New therapeutic strategies for Mycobacterium abscessus pulmonary diseases - Untapping the mycolic acid pathway.
Matthéo AlcarazThomas E EdwardsLaurent KremerPublished in: Expert review of anti-infective therapy (2023)
There is an increasing body of evidence validating the mycolic acid pathway as an attractive drug target to be further exploited for M. abscessus lung disease treatments. The NITD-916 studies provide a proof-of-concept that direct inhibitors of InhA are efficient in vitro, in macrophages and in zebrafish. Future work is now required to improve the activity and pharmacological properties of these inhibitors and their evaluation in pre-clinical models.